Clinical Trials

Neuroendocrine Tumors

NCT05773274 2026-03-18

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

100 enrolled

Metastatic Digestive System Neuroendocrine Tumor G1

NCT06406465 2026-03-18

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

60 enrolled

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT03412877 2026-03-17

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

BreastEndocrineGynecologicNETPlasma cellThoracic

285 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Phase 1 Recruiting

18 enrolled

BreastCNSDermatologicEndocrineHead & NeckNETThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

NCT04665739 2026-03-17

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

70 enrolled

Phase 1 Active not recruiting

Advanced Lung Neuroendocrine Tumor

NCT04750954 2026-03-17

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

29 enrolled

Neuroendocrine Tumors

NCT05746208 2026-03-17

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

29 enrolled

Neuroendocrine Tumors

NCT00923026 2026-03-11

Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies

Enrolling by invitation

1,150 enrolled

DermatologicEndocrineNET

Adenocarcinoma, Carcinoma, Melanoma, Neuroendocrine Tumors

NCT02402920 2026-03-10

Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer

Phase 1 Completed

83 enrolled 13 charts

BreastEndocrineGenitourinaryNET

Neuroendocrine Tumors

NCT05160480 2026-03-10

A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG

Enrolling by invitation

9 enrolled

Breast Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors

NCT07087054 2026-03-10

CAREFNDR

Phase 3 Recruiting

141 enrolled

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

NCT07129252 2026-03-10

BRAVESST2

Phase 1/2 Recruiting

150 enrolled

Neoplasm Metastasis, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT06448208 2026-03-09

Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors

Active not recruiting

11 enrolled

Phase 2 Active not recruiting

Neuroendocrine Tumors

NCT02568267 2026-03-06

STARTRK-2

534 enrolled 1 FDA

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT05918302 2026-03-06

LEVEL

Phase 3 Recruiting

120 enrolled

Thymus Neoplasms, Neuroendocrine Tumors

NCT05988918 2026-03-06

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

66 enrolled

EndocrineGastrointestinalLymphoidNET

Gastro-enteropancreatic neuroendocrine tumor, Adenoma, Islet Cell, Somatostatinoma, Carcinoma, Adenosquamous

NCT06784752 2026-03-06

NETTER-3

Phase 3 Recruiting

240 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Lymphoma, Follicular

NCT07450287 2026-03-04

CardioNETPOL

Not yet recruiting

120 enrolled

Carcinoid Heart Disease, Heart Failure, Heart Valve Diseases, Neuroendocrine Tumors, Serotonin Syndrome

NCT03211988 2026-03-02

Entinostat Neuroendocrine (NE) Tumor

Phase 2 Terminated

5 enrolled 9 charts

CNSDermatologicEndocrineLymphoidMyeloidNETSarcoma

Recurrence, Neuroendocrine Tumors

NCT02402244 2026-02-27

Project: Every Child for Younger Patients With Cancer

Recruiting

75,000 enrolled

Carcinoma in Situ, Ganglioneuroma, Lymphoproliferative Disorders, Melanoma, Myeloproliferative Disorders, Neoplasms, Pheochromocytoma, Central Nervous System Neoplasms, Nephroma, Mesoblastic, Desmoid Tumors, Neuroendocrine Tumors

NCT03833700 2026-02-27

A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

Phase 1 Active not recruiting

70 enrolled

EndocrineGastrointestinalNETSarcoma

Gastro-enteropancreatic neuroendocrine tumor, Digestive System Neoplasms, Carcinoma, Hepatocellular, Colorectal Neoplasms, Desmoid Tumors, Adrenocortical Carcinoma

NCT04969887 2026-02-27

MOST-CIRCUIT

Phase 2 Active not recruiting

240 enrolled

Genital Neoplasms, Female, Neuroendocrine Tumors

NCT06943755 2026-02-27

STELLAR-311

Phase 2/3 Recruiting

440 enrolled

Adenoma, Islet Cell, Neoplasm Metastasis, Neuroendocrine Tumors

NCT07314164 2026-02-27

Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment

Recruiting

150 enrolled

Neuroendocrine Tumors

NCT04074135 2026-02-24

Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

740 enrolled

von Hippel-Lindau Disease, Pancreatic Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT07429851 2026-02-24

LINEAR

Recruiting

34 enrolled

Neuroendocrine Carcinoma of Lung

NCT04907643 2026-02-20

Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

Phase NA Recruiting

360 enrolled

Cancer Pain, Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Liver Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Rectal Neoplasms, Recurrence, Stomach Neoplasms, Neuroendocrine Tumors, Visceral Pain

NCT07377487 2026-02-20

INDIGO

Phase NA Recruiting

51 enrolled

BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Carcinoma, Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Colorectal Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT05000294 2026-02-18

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Phase 1/2 Suspended

29 enrolled

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT03206060 2026-02-17

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma